{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:04:52Z","timestamp":1790719492579,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10096-019-03701-0","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T23:07:18Z","timestamp":1568243238000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase\u2013producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis"],"prefix":"10.1007","volume":"39","author":[{"given":"O.","family":"Senard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lesprit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Lescure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Therby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Fihman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Oubaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lepeule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"key":"3701_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2334-8-12","volume":"8","author":"M Etienne","year":"2008","unstructured":"Etienne M, Chavanet P, Sibert L, Michel F, Levesque H, Lorcerie B, Doucet J, Pfitzenmeyer P, Caron F (2008) Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis 8:12. \nhttps:\/\/doi.org\/10.1186\/1471-2334-8-12","journal-title":"BMC Infect Dis"},{"issue":"6","key":"3701_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000074526","volume":"49","author":"K Charalabopoulos","year":"2003","unstructured":"Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N (2003) Penetration of antimicrobial agents into the prostate. Chemotherapy 49(6):269\u2013279. \nhttps:\/\/doi.org\/10.1159\/000074526","journal-title":"Chemotherapy"},{"issue":"3","key":"3701_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","volume":"8","author":"JD Pitout","year":"2008","unstructured":"Pitout JD, Laupland KB (2008) Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8(3):159\u2013166","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"3701_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s1473-3099(14)70950-8","volume":"15","author":"PN Harris","year":"2015","unstructured":"Harris PN, Tambyah PA, Paterson DL (2015) Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 15(4):475\u2013485. \nhttps:\/\/doi.org\/10.1016\/s1473-3099(14)70950-8","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"3701_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/420816","volume":"39","author":"DL Paterson","year":"2004","unstructured":"Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL (2004) Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 39(1):31\u201337","journal-title":"Clin Infect Dis"},{"issue":"7","key":"3701_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/cid\/cix034","volume":"64","author":"PD Tamma","year":"2017","unstructured":"Tamma PD, Rodriguez-Bano J (2017) The use of noncarbapenem beta-lactams for the treatment of extended-spectrum beta-lactamase infections. Clin Infect Dis 64(7):972\u2013980. \nhttps:\/\/doi.org\/10.1093\/cid\/cix034","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3701_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.medmal.2018.03.005","volume":"48","author":"F. Caron","year":"2018","unstructured":"Caron F, Galperine T, Flateau C, Azria R, Bonacorsi S, Bruyere F, Cariou G, Clouqueur E, Cohen R, Doco-Lecompte T, Elefant E, Faure K, Gauzit R, Gavazzi G, Lemaitre L, Raymond J, Senneville E, Sotto A, Subtil D, Trivalle C, Merens A, Etienne M (2018) Practice guidelines for the management of adult community-acquired urinary tract infections. Med Mal Infect. \nhttps:\/\/doi.org\/10.1016\/j.medmal.2018.03.005","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"issue":"5893","key":"3701_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/bmj.4.5893.653","volume":"4","author":"J Kosmidis","year":"1973","unstructured":"Kosmidis J, Hamilton-Miller JM, Gilchrist JN, Kerry DW, Brumfitt W (1973) Cefoxitin, a new semi-synthetic cephamycin: an in-vitro and in-vivo comparison with cephalothin. Br Med J 4(5893):653\u2013655","journal-title":"Br Med J"},{"issue":"5","key":"3701_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/AAC.34.5.858","volume":"34","author":"GA Jacoby","year":"1990","unstructured":"Jacoby GA, Carreras I (1990) Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 34(5):858\u2013862","journal-title":"Antimicrob Agents Chemother"},{"issue":"11\u201312","key":"3701_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.medmal.2014.09.004","volume":"44","author":"R Lepeule","year":"2014","unstructured":"Lepeule R, Leflon-Guibout V, Vanjak D, Zahar JR, Lafaurie M, Besson C, Lefort A (2014) Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use. Med Mal Infect 44(11\u201312):530\u2013534. \nhttps:\/\/doi.org\/10.1016\/j.medmal.2014.09.004","journal-title":"Med Mal Infect"},{"issue":"5","key":"3701_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"Suppl 1","key":"3701_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/PL00003795","volume":"27","author":"I Matot","year":"2001","unstructured":"Matot I, Sprung CL (2001) Definition of sepsis. Intensive Care Med 27(Suppl 1):S3\u2013S9","journal-title":"Intensive Care Med"},{"issue":"10","key":"3701_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","volume":"137","author":"ND Friedman","year":"2002","unstructured":"Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ (2002) Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137(10):791\u2013797","journal-title":"Ann Intern Med"},{"key":"3701_CR14","unstructured":"European Manual of Clinical Microbiology (2012)"},{"key":"3701_CR15","first-page":"58","volume-title":"French Society for Microbiology","author":"RCJ Bonnet","year":"2013","unstructured":"Bonnet RCJ, Chardon H, Chidiac C, Courvalin P, Dabernat H (2013) Recommendations of Antibiogram Committee. In: French Society for Microbiology, p 58"},{"issue":"3","key":"3701_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1128\/JCM.02130-10","volume":"49","author":"H Garrec","year":"2011","unstructured":"Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J (2011) Comparison of nine phenotypic methods for detection of extended-spectrum beta-lactamase production by Enterobacteriaceae. J Clin Microbiol 49(3):1048\u20131057. \nhttps:\/\/doi.org\/10.1128\/JCM.02130-10","journal-title":"J Clin Microbiol"},{"key":"3701_CR17","first-page":"3","volume":"2012","author":"R Lepeule","year":"2012","unstructured":"Lepeule R, Ruppe E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B (2012) Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15 type extended-spectrum beta-lactamase. Antimicrob Agents Chemother 2012:3","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3701_CR18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s10096-014-2094-y","volume":"33","author":"B Pilmis","year":"2014","unstructured":"Pilmis B, Parize P, Zahar JR, Lortholary O (2014) Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 33(8):1263\u20131265. \nhttps:\/\/doi.org\/10.1007\/s10096-014-2094-y","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"3701_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3109\/23744235.2015.1062133","volume":"47","author":"S Kerneis","year":"2015","unstructured":"Kerneis S, Valade S, Geri G, Compain F, Lavollay M, Rostane H, Carbonnelle E, Mainardi JL (2015) Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Dis (Lond) 47(11):789\u2013795. \nhttps:\/\/doi.org\/10.3109\/23744235.2015.1062133","journal-title":"Infect Dis (Lond)"},{"issue":"4","key":"3701_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.medmal.2016.04.008","volume":"46","author":"A Mambie","year":"2016","unstructured":"Mambie A, Vuotto F, Poitrenaud D, Weyrich P, Cannesson O, Dessein R, Faure K, Guery B, Galperine T (2016) Cefoxitin: an alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Med Mal Infect 46(4):215\u2013219. \nhttps:\/\/doi.org\/10.1016\/j.medmal.2016.04.008","journal-title":"Med Mal Infect"},{"issue":"6","key":"3701_CR21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ijantimicag.2018.01.008","volume":"51","author":"E Demonchy","year":"2018","unstructured":"Demonchy E, Courjon J, Ughetto E, Durand M, Risso K, Garraffo R, Roger PM (2018) Cefoxitin-based antibiotic therapy for extended-spectrum beta-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study. Int J Antimicrob Agents 51(6):836\u2013841. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.008","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"3701_CR22","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1128\/aac.00701-15","volume":"59","author":"Y Matsumura","year":"2015","unstructured":"Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S (2015) Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother 59(9):5107\u20135113. \nhttps:\/\/doi.org\/10.1128\/aac.00701-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3701_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12879-016-1770-1","volume":"16","author":"T Fukuchi","year":"2016","unstructured":"Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G (2016) Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. BMC Infect Dis 16(1):427. \nhttps:\/\/doi.org\/10.1186\/s12879-016-1770-1","journal-title":"BMC Infect Dis"},{"issue":"5","key":"3701_CR24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/infdis\/159.5.1005","volume":"159","author":"B Pangon","year":"1989","unstructured":"Pangon B, Bizet C, Bure A, Pichon F, Philippon A, Regnier B, Gutmann L (1989) In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis 159(5):1005\u20131006","journal-title":"J Infect Dis"},{"issue":"2","key":"3701_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jac\/dkm215","volume":"60","author":"CH Lee","year":"2007","unstructured":"Lee CH, Chu C, Liu JW, Chen YS, Chiu CJ, Su LH (2007) Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases. J Antimicrob Chemother 60(2):410\u2013413. \nhttps:\/\/doi.org\/10.1093\/jac\/dkm215","journal-title":"J Antimicrob Chemother"},{"issue":"B","key":"3701_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/jac\/4.suppl_B.69","volume":"4","author":"JJ Schrogie","year":"1978","unstructured":"Schrogie JJ, Davies RO, Yeh KC, Rogers D, Holmes GI, Skeggs H, Martin CM (1978) Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother 4(B):69\u201378","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"3701_CR27","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1128\/aac.02509-14","volume":"58","author":"H Guet-Revillet","year":"2014","unstructured":"Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, Bille E, Jullien V, Zahar JR (2014) Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 58(8):4899\u20134901. \nhttps:\/\/doi.org\/10.1128\/aac.02509-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3701_CR28","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/jac\/dkl381","volume":"58","author":"CH Lee","year":"2006","unstructured":"Lee CH, Su LH, Tang YF, Liu JW (2006) Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 58(5):1074\u20131077. \nhttps:\/\/doi.org\/10.1093\/jac\/dkl381","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"3701_CR29","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/cid\/civ007","volume":"60","author":"F Perez","year":"2015","unstructured":"Perez F, Bonomo RA (2015) Editorial commentary: bloodstream infection caused by extended-spectrum beta-lactamase-producing gram-negative bacteria: how to define the best treatment regimen? Clin Infect Dis 60(9):1326\u20131329. \nhttps:\/\/doi.org\/10.1093\/cid\/civ007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3701_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399\u2013424. \nhttps:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivar Behav Res"},{"issue":"6","key":"3701_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ijantimicag.2018.08.026","volume":"52","author":"PL Woerther","year":"2018","unstructured":"Woerther PL, Lepeule R, Burdet C, Decousser JW, Ruppe E, Barbier F (2018) Carbapenems and alternative beta-lactams for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation resistance? Int J Antimicrob Agents 52(6):762\u2013770. \nhttps:\/\/doi.org\/10.1016\/j.ijantimicag.2018.08.026","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"3701_CR32","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1128\/AAC.01823-12","volume":"57","author":"L Armand-Lefevre","year":"2013","unstructured":"Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plesiat P, Andremont A (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57(3):1488\u20131495","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03701-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T17:35:19Z","timestamp":1599759319000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03701-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["3701"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03701-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures were in accordance with the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"According to French Health Public Law (CSP Article L1121-1), this type of study did not require specific informed consent or ethics committee approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}